John S. Munger, MD

  • Specialties: Critical Care, Pulmonary Medicine
  • Language: English
  • Phone: 212-263-7951

Credentials

Positions
  • Associate Professor, Department of Medicine
  • Associate Professor, Department of Cell Biology
  • Director, Honors Program
  • Director, Physician-Scientist Training Program
Board Certifications
  • American Board of Internal Medicine (Critical Care Medicine), 1991
  • American Board of Internal Medicine (Pulmonary Disease), 1990
  • American Board of Internal Medicine - Internal Medicine, 1985
Education and Training
  • Fellowship, Brigham & Womens Hospital, Pulmonary, Crit Care, 1991
  • MD from Washington University, 1982
Departments

Is this your profile?

Edit profile

Is this your profile?

Edit profile

Locations and Appointments

View Insurance Plans Accepted
  • Aetna
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Affinity
    • Affinity
    • Affinity Exchange- Essential
  • Agewell
    • Agewell
  • Alphacare
    • Alphacare
  • Cigna
    • Cigna EPO/POS
    • Cigna PPO
  • ElderPlan
    • ElderPlan
  • Empire Blue Cross Blue Shield
    • Empire Blue Cross Blue Shield EPO
    • Empire Blue Cross Blue Shield HMO
    • Empire Blue Cross Blue Shield HealthPlus
    • Empire Blue Cross Blue Shield HealthPlus Essential
    • Empire Blue Cross Blue Shield Indemnity
    • Empire Blue Cross Blue Shield MediBlue
    • Empire Blue Cross Blue Shield POS
    • Empire Blue Cross Blue Shield PPO
    • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis
    • Fidelis Child Health
    • Fidelis Essential
    • Fidelis Exchange
    • Fidelis Family Health
    • Fidelis Medicaid
    • Fidelis Medicare
  • GHI
    • GHI CBP
    • GHI HMO
  • HIP
    • HIP Access I
    • HIP Access II
    • HIP Child Health
    • HIP EPO/PPO
    • HIP HMO
    • HIP POS
  • HealthSmart
    • HealthSmart (WTC)
  • Healthfirst
    • Healthfirst
    • Healthfirst Essential
  • Hotel Trades
    • Hotel Trades
  • Humana
    • Humana Medicare
  • Local 1199
    • Local 1199 PPO
  • MagnaCare
    • MagnaCare PPO
  • Medicaid
    • NY Medicaid
  • Medicare
    • Medicare
  • MetroPlus
    • MetroPlus Child Health
    • MetroPlus Essential
    • MetroPlus Exchange Plans
    • MetroPlus Family Health
    • MetroPlus Medicaid
    • MetroPlus Medicare
  • MultiPlan/PHCS
    • MultiPlan/PHCS PPO
  • NYS
    • NYS Empire Plan
  • Oxford
    • Oxford Freedom
    • Oxford Liberty
    • Oxford Medicare
  • PHP
    • PHP
  • Tricare
    • Tricare
  • UHC
    • UnitedHealthcare Community & State Plan
    • UnitedHealthcare EPO
    • UnitedHealthcare HMO
    • UnitedHealthcare Medicare
    • UnitedHealthcare POS
    • UnitedHealthcare PPO
    • UnitedHealthcare Top Tier
  • VNS
    • Visiting Nurse Service (VNS) Medicare
  • Village Caremax
    • Village Caremax
  • WellCare
    • WellCare Child Health
    • WellCare Family Health
    • WellCare Medicaid
    • WellCare Medicare
  • Wellcare
    • Wellcare Exchange
NYU Pulmonary & Critical Care Associates

530 1st Avenue, HCC, Suite 5D
New York, NY 10016

NYU Critical Care Associates

550 1st Avenue
New York, NY 10016

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

Research My Research

Interests

how integrins activate latent TGFβ1 and TGFβ3 during development and in disease, cancer

Research Summary

Our lab studies how latent forms of TGFβ are activated by integrins in vivo.

TGFβ is a ubiquitously produced growth factor with important roles in pathologic processes such as cancer, fibrosis and autoimmunity, and in normal development, wound repair and homeostasis. There are three TGFβ isoforms, and all are secreted in a latent form. Latency is the result of a noncovalent association of the growth factor with its propeptide, which is called latency-associate peptide (LAP). TGFβ must be released from LAP before it can bind TGFβ receptors. The activation step is highly regulated but the specific activation mechanisms involved vivo have been poorly understood.

We discovered that αvβ6, a cell surface adhesion molecule in the integrin family, can activate latent TGFβ1 and TGFβ3 by interacting with an RGD sequence in the TGFβ1 and TGFβ3 LAPs. αvβ6 is expressed in epithelia, particularly after injury. Mice lacking αvβ6 have lung inflammation and are protected from lung fibrosis due to a relative lack of TGFβ signaling in the lung.

We also collaborated with S. Nishimura's lab at UCSF to show that a second RGD-binding integrin, αvβ8, activates TGFβ1 and TGFβ3. Mice lacking this integrin have abnormalities in vascular development. Comparison of knockouts of the two TGFβs and the two β integrin subunits reveals several partially or completely overlapping abnormalities in palate closure, immune regulation, and vascular development, suggesting that αvβ6 and αvβ8 are key TGFβ1/3 activators in vivo.

To determine the role of all RGD-binding integrins in the activation of latent TGFβ1, we made mice with a knock-in mutation of the TGFβ1 gene that changes the RGD site to RGE. These mice produce normal amounts of latent TGFβ1, but it cannot be activated by RGD-binding integrins. Strikingly, the mice have the same abnormalities seen in TGFβ1-null mice, indicating that RGD-binding integrins are indispensable for TGFβ1 activation.

We are currently further exploring the connection between these two integrins and the two RGD-containing TGFβ isoforms by generating mice with combined TGFβ1/3 mutations and mice with combined αvβ6/αvβ8 deficits. Our results support a tight functional system involving the two TGFβs and the two activating integrins. For example, mice with combined αvβ6/αvβ8 deficits have completely penetrant cleft palate, and mice with combined TGFβ1/3 mutations have the CNS vascular changes seen in αvβ8-null mice.

We are now focusing on the immune phenotype of mice lacking function of both αvβ6 and αvβ8. These mice develop severe autoimmune reactions that appear identical to (if not more severe than) those of TGFβ1-null mice. Also, we are testing the effectiveness of an inhibitory anti-αvβ6 mAb, developed by Biogen Idec, in mouse models of lung fibrosis. We find that anti-αvβ6 treatment effectively prevents radiation-induced lung fibrosis in mice, raising the possibility that such treatment might benefit patients with various forms of lung fibrosis.

 

 

Research Interests Timeline

These focus areas and their associated publications are derived from PubMed and the MeSH term library.
represents one publication
Loading...

Publications

  • Sonic Hedgehog Signaling Regulates Myofibroblast Function During Alveolar Septum Formation in Murine Postnatal Lung

    Kugler, Matthias C; Loomis, Cynthia A; Zhao, Zhicheng; Cushman, Jennifer C; Liu, Li; Munger, John S Kugler, Matthias C; Loomis, Cynthia A; Zhao, Zhicheng; Cushman, Jennifer C; Liu, Li; Munger, John S
    American journal of respiratory cell & molecular biology. 2017 Apr 5. ?-?

  • Autoantibodies against tumor-associated antigens in the early detection of lung cancer

    Dai, Liping; Tsay, Jun-Chieh J; Li, Jitian; Yie, Ting-An; Munger, John S; Pass, Harvey; Rom, William N; Zhang, Yi; Tan, Eng M; Zhang, Jian-Ying Dai, Liping; Tsay, Jun-Chieh J; Li, Jitian; Yie, Ting-An; Munger, John S; Pass, Harvey; Rom, William N; Zhang, Yi; Tan, Eng M; Zhang, Jian-Ying
    Lung cancer. 2016 Sep. 99: 172-179

  • Reduced lung function in smokers in a lung cancer screening cohort with asbestos exposure and pleural plaques

    Rom, William N; Lopatin, Sarah; Tsay, Jun-Chieh J; Addrizzo-Harris, Doreen; Munger, John S; Pass, Harvey Rom, William N; Lopatin, Sarah; Tsay, Jun-Chieh J; Addrizzo-Harris, Doreen; Munger, John S; Pass, Harvey
    American journal of industrial medicine. 2016 Mar. 59 (3): 178-185

Read All Publications (50)